Showing 1 - 1 of 1 results
Class (Stereo):
CHEMICAL (ABSOLUTE)
Encorafenib, also known as BRAFTOVI or LGX818, is an orally available mutated BRaf V600E inhibitor with potential antineoplastic activity, which was developed by Novartis. LGX818 possesses selective anti-proliferative and apoptotic activity in cells ...